Literature DB >> 28606879

Can immunosuppression be stopped after liver transplantation?

Pierre-Alain Clavien1, Xavier Muller2, Michelle L de Oliveira2, Philipp Dutkowski2, Alberto Sanchez-Fueyo3.   

Abstract

Liver transplantation has improved dramatically over the past three decades, mainly as a result of advances in surgical techniques and management of post-transplant complications. The focus has now turned towards rescuing additional organs in the face of scarce organ supply, or prevention of long-term toxicity associated with immunosuppression. The liver appears to be privileged in terms of immune tolerance, with a low incidence of antibody-mediated rejection, which is in sharp contrast to other solid organ transplants, such as kidney, lung, and heart transplants. However, tolerogenic processes remain poorly understood, and strategies for complete drug withdrawal should be selected carefully to avoid graft rejection. In this Review, we summarise the current understanding of liver-specific immune responses and provide an outlook on future approaches.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28606879     DOI: 10.1016/S2468-1253(16)30208-4

Source DB:  PubMed          Journal:  Lancet Gastroenterol Hepatol


  7 in total

1.  Combination Therapy Is the New Gene Therapy?

Authors:  Giuseppe Ronzitti; Federico Mingozzi
Journal:  Mol Ther       Date:  2017-12-20       Impact factor: 11.454

Review 2.  Using a weaning immunosuppression protocol in liver transplantation recipients with hepatocellular carcinoma: a compromise between the risk of recurrence and the risk of rejection?

Authors:  Roberta Angelico; Alessandro Parente; Tommaso Maria Manzia
Journal:  Transl Gastroenterol Hepatol       Date:  2017-09-21

3.  Linked sensitization by memory CD4+ T cells prevents costimulation blockade-induced transplantation tolerance.

Authors:  Michael S Andrade; James S Young; Jared M Pollard; Dengping Yin; Maria-Luisa Alegre; Anita S Chong
Journal:  JCI Insight       Date:  2022-06-08

4.  A Mixed-chimerism Protocol Utilizing Thymoglobulin and Belatacept Did Not Induce Lung Allograft Tolerance, Despite Previous Success in Renal Allotransplantation.

Authors:  Wiebke Sommer; Jane M O; Kurt B Pruner; Abbas Dehnadi; Kyu Ha Huh; Kortney A Robinson; Isabel Hanekamp; Ivy Rosales; Alison S Bean; Josh Paster; Tetsu Oura; Rex Neal Smith; Robert Colvin; Gilles Benichou; Tatsuo Kawai; Joren C Madsen; James S Allan
Journal:  Transplant Direct       Date:  2021-05-25

5.  Ex vivo generation of regulatory T cells from liver transplant recipients using costimulation blockade.

Authors:  Katsuyoshi Shimozawa; Laura Contreras-Ruiz; Sofia Sousa; Ruan Zhang; Urvashi Bhatia; Kerry C Crisalli; Lisa L Brennan; Laurence A Turka; James F Markmann; Eva C Guinan
Journal:  Am J Transplant       Date:  2021-09-27       Impact factor: 9.369

6.  Chronic rejection after liver transplantation: Opening the Pandora's box.

Authors:  Roberta Angelico; Bruno Sensi; Tommaso M Manzia; Giuseppe Tisone; Giuseppe Grassi; Alessandro Signorello; Martina Milana; Ilaria Lenci; Leonardo Baiocchi
Journal:  World J Gastroenterol       Date:  2021-12-07       Impact factor: 5.742

Review 7.  Impact of Machine Perfusion on the Immune Response After Liver Transplantation - A Primary Treatment or Just a Delivery Tool.

Authors:  Rebecca Panconesi; Mauricio Flores Carvalho; Daniele Dondossola; Paolo Muiesan; Philipp Dutkowski; Andrea Schlegel
Journal:  Front Immunol       Date:  2022-07-08       Impact factor: 8.786

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.